Targovax is invited to present at Neoantigen Summit Europe, DNB SME Conference and BIO-Europe Spring
Oslo, Norway, 19 March 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that members of its senior management team is invited to present at upcoming conferences.13th Annual BIO-Europe Spring, Vienna, AustriaDate: 25 March 2019Presenter: Øystein Soug (CEO)Panel discussion:- Art of multitrack deal: Keys to maximizing the value of your company- Time: 14:45 CETDNB's 15th Annual Small & Medium Enterprises (SME) Conference, Oslo, NorwayDate: 4 April 2019Presenter: Øystein